Redeye: Surgical Science Q2 2024 - Solid sequential recovery, decent outlook
Redeye updates its estimates following Surgical Science’s Q2 2024 report, which featured a sequential recovery after the company’s weak Q1. Potential large orders in Educational Products might fuel sales growth in H2 2024e and 2025e. Further, Intuitive’s broader da Vinci 5 rollout should boost Industry/OEM growth in 2025e. We finetune our estimates and valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/